Termination of pregnancy
Cultural acknowledgement

We acknowledge the Traditional Custodians of the land on which we work and pay our respect to the Aboriginal and Torres Strait Islander elders past, present and emerging.

Disclaimer

This guideline is intended as a guide and provided for information purposes only. The information has been prepared using a multidisciplinary approach with reference to the best information and evidence available at the time of preparation. No assurance is given that the information is entirely complete, current, or accurate in every respect.

The guideline is not a substitute for clinical judgement, knowledge and expertise, or medical advice. Variation from the guideline, taking into account individual circumstances, may be appropriate.

This guideline does not address all elements of standard practice and accepts that individual clinicians are responsible for:

- Providing care within the context of locally available resources, expertise, and scope of practice
- Supporting consumer rights and informed decision making, including the right to decline intervention or ongoing management
- Advising consumers of their choices in an environment that is culturally appropriate and which enables comfortable and confidential discussion. This includes the use of interpreter services where necessary
- Ensuring informed consent is obtained prior to delivering care
- Meeting all legislative requirements and professional standards
- Applying standard precautions, and additional precautions as necessary, when delivering care
- Documenting all care in accordance with mandatory and local requirements

Queensland Health disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this guideline, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.
Legal requirements ToP Act 2018

- A medical practitioner may perform a termination upon request

At or after 22+1 weeks
- A medical practitioner may perform a termination if, in consultation with another medical practitioner, all the below circumstances are met
  - Circumstances both medical practitioners must consider:
    - All relevant medical circumstances
    - The woman’s current and future physical, psychological and social circumstances
    - Professional standards and guidelines relevant to the practitioners in relation to termination

Pre-termination assessment

- Confirm pregnancy
- Medical, obstetric, sexual history
- Psychosocial history
  - Screening for domestic violence or reproductive coercion
  - Refer as appropriate

Examination/Investigations
- Determine gestational age
- Confirm intrauterine pregnancy (exclude ectopic)
- Routine antenatal bloods
- Ultrasound scan (USS)
- Offer opportunistic health care

Information
- Provide accurate, non-judgemental, easy to understand information on:
  - Options for the pregnancy (including palliation/adoption)
  - Methods of termination
  - Contraception
  - Post-termination care

Co-ordinate referrals
- As clinically indicated
- Offer confidential non-judgemental counselling
- Offer formal mental health referral
- Refer to other services (e.g., private service providers)
- Discuss fetal autopsy

Surgical or medical procedure
- Consider:
  - Gestation of pregnancy
  - Clinical indications
  - Preferences of the woman
  - Service level capability and expertise
  - Antibiotics for surgical procedures, if required

Consent
- Consider issues of capacity
- Consider adequacy of information provision and counselling
- If less than 18 years:
  - Assess Gillick Competence
  - Assess mandatory reporting requirements

Co-ordinate referrals
- Consider referrals specialist care, termination procedure, psychological support/counselling

Discuss
- Follow up
- Contraception options

Post-termination care
- Histopathology
- Rh D immunoglobulin
- Analgesia requirements
- Provide after care advice
- Discuss contraceptive options
- Provide advice on accessing psychological care
- Recommend follow-up
- Refer as required

Conscientious objection
- Disclose objection if termination is requested
- Without delay, transfer care to other service or to provider who does not have conscientious objection

ToP: termination of pregnancy, Rh D: rhesus D
Flowchart: Medical termination with MS-2 Step

**Woman requests termination healthcare**
- Offer non-directive pregnancy related counselling
- Urinary pregnancy test
- Ultrasound scan (USS)
- Counsel about termination options

**Clinical assessment**
- Review history (medical, sexual, obstetric)
- Psychosocial history
  - Refer as appropriate
- Exclude contraindications
- Obtain consent
- Remove IUD
- Discuss contraception
- Routine antenatal bloods
  - If Rh D-ve, Rh D immunoglobulin required
- Offer opportunistic health care
  - Cervical screening test
  - STI screening
  - Smoking cessation advice

**MS-2 step**
- Provide instructions for self administration
- Advise on:
  - Pain management
  - Expected bleeding
  - Possible complications
  - Accessing emergency care
  - Seeking support if no onset of bleeding within 24 hours after Misoprostol
  - Fertility, contraception and resuming sexual activity
  - Need for follow-up including non-judgemental psychosocial support/counselling or specialist care

**Perfom clinical assessment for MToP**

**Follow-up**
- Face to face or remote consult
- Confirm wellbeing
  - β-hCG (expect 80% drop)
  - Bleeding ceased
  - USS if indicated
- Offer contraception (e.g. short or long acting options)
  - Can commence immediately

**Further follow-up (as indicated)**
- Bleeding ongoing consider:
  - USS
- Consider referral for:
  - Surgical intervention or
  - Further misoprostol dose

**Conscientious objection**
- Disclose objection if termination is requested
- Without delay, transfer care to other service or to provider who does not have conscientious objection


Queensland Clinical Guidelines: Medical termination with MS-2 Step Flowchart: F19.21-2-V2-R24
Table of Contents
Abbreviations ....................................................................................................................................................... 7
Definition of terms.................................................................................................................................................. 7
1 Introduction....................................................................................................................................................... 8
  1.1 Background .................................................................................................................................................. 8
2 Queensland law.................................................................................................................................................. 8
  2.1 Performance of a termination .................................................................................................................. 8
  2.2 Medical practitioner responsibilities .................................................................................................... 9
  2.3 Registered health practitioners assisting ............................................................................................. 9
  2.4 Conscientious objection ........................................................................................................................ 10
  2.5 Emergency care involving termination ............................................................................................... 11
  2.6 Safe access zones .................................................................................................................................... 11
  2.7 Non-compliance with the ToP Act........................................................................................................ 12
3 Clinical standards .......................................................................................................................................... 13
4 Individual case considerations .................................................................................................................... 14
  4.1 Consent ....................................................................................................................................................... 14
  4.2 Young person less than 14 years ............................................................................................................. 15
  4.3 Suspicion of child abuse ......................................................................................................................... 15
  4.4 Special circumstances ............................................................................................................................ 16
  4.5 Documentation of decisions .................................................................................................................. 16
5 Pre-termination assessment ........................................................................................................................ 17
  5.1 Psychological support ............................................................................................................................ 18
  5.1.1 Psychological sequelae ...................................................................................................................... 19
  5.2 Method selection ...................................................................................................................................... 20
    5.2.1 Other considerations for method selection ..................................................................................... 20
  5.3 MToP and SToP risks and complications .............................................................................................. 21
  5.4 Fetal considerations ............................................................................................................................... 22
    5.4.1 Birth registration ............................................................................................................................... 22
    5.4.2 Transport and management of fetal remains .................................................................................. 22
    5.4.3 Other fetal considerations ............................................................................................................... 23
6 Medical termination ...................................................................................................................................... 24
  6.1 Practitioner requirements ....................................................................................................................... 24
  6.2 MToP precautions ................................................................................................................................... 24
  6.3 MToP in the outpatient setting ............................................................................................................... 24
  6.4 MToP pre-dosage care ........................................................................................................................... 25
  6.5 MToP at 63 days gestation or less .......................................................................................................... 26
  6.6 MToP after 63 days gestation ................................................................................................................ 27
    6.6.1 Care during MToP ............................................................................................................................ 27
    6.6.2 MToP regimen for women at risk of uterine rupture ...................................................................... 27
    6.6.3 MToP regimen for women not known to be at risk of uterine rupture ........................................... 28
7 Surgical termination ....................................................................................................................................... 29
  7.1 SToP pre-procedure care ........................................................................................................................ 29
  7.2 Cervical priming for SToP ..................................................................................................................... 29
    7.2.1 Misoprostol prior to SToP ................................................................................................................ 29
    7.2.2 Mifepristone and misoprostol prior to SToP .................................................................................. 30
  7.3 Surgical curettage ..................................................................................................................................... 30
8 MToP and SToP post-termination care........................................................................................................... 31
  8.1 Contraception .......................................................................................................................................... 31
  8.2 Discharge preparation and follow-up .................................................................................................... 32
References ......................................................................................................................................................... 33
Acknowledgements ........................................................................................................................................... 35
List of Tables

Table 1. Performance of a termination .............................................. 8
Table 2. Medical practitioner responsibilities .................................. 9
Table 3. Assisting with a termination ............................................... 9
Table 4. Conscientious objection ...................................................... 10
Table 5. Emergency care ................................................................. 11
Table 6. Safe access zone ............................................................... 11
Table 7. Non-compliance ............................................................... 12
Table 8. Clinical standards ............................................................ 13
Table 9. Consent .......................................................................... 14
Table 10. Young person less than 14 years ........................................ 15
Table 11. Suspicion of abuse .......................................................... 15
Table 12. Special circumstances .................................................... 16
Table 13. Documentation .............................................................. 16
Table 14. Clinical assessment prior to termination ......................... 17
Table 15. Information and counselling ........................................... 18
Table 16. Psychological healthcare ................................................ 19
Table 17. Methods of termination .................................................. 20
Table 18. Considerations for selection ............................................ 20
Table 19. Risks and complications ................................................ 21
Table 20. Registration requirements .............................................. 22
Table 21. Management of fetal remains/tissue ................................. 22
Table 22. Fetal considerations ........................................................ 23
Table 23. Precautions for medical termination ............................... 24
Table 24. Healthcare setting .......................................................... 24
Table 25. MToP pre-dosage care .................................................... 25
Table 26. MS-2 Step for MToP ....................................................... 26
Table 27. MToP considerations after 63 days gestation .................... 27
Table 28. MToP with risk of uterine rupture .................................... 27
Table 29. MToP with no known risk of uterine rupture .................... 28
Table 30. SToP pre-procedure care ................................................. 29
Table 31. Cervical priming for SToP ............................................... 29
Table 32. Misoprostol alone for cervical priming prior to surgical termination ........................................... 29
Table 33. Mifepristone and misoprostol for cervical priming prior to surgical termination ......................... 30
Table 34. Considerations for surgical termination ......................... 30
Table 35. Post-termination care considerations ............................... 31
Table 36. Contraception provision .................................................. 31
Table 37. Discharge preparation ..................................................... 32
### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-hCG</td>
<td>Beta human chorionic gonadotropin</td>
</tr>
<tr>
<td>CSCF</td>
<td>Clinical Services Capability Framework</td>
</tr>
<tr>
<td>FMH</td>
<td>Feto-maternal haemorrhage</td>
</tr>
<tr>
<td>GP</td>
<td>General Practitioner</td>
</tr>
<tr>
<td>HHS</td>
<td>Hospital and Health Services</td>
</tr>
<tr>
<td>MToP</td>
<td>Medical termination of pregnancy</td>
</tr>
<tr>
<td>Rh D</td>
<td>Rhesus immunoglobulin</td>
</tr>
<tr>
<td>STI</td>
<td>Sexually transmitted infection(s)</td>
</tr>
<tr>
<td>SToP</td>
<td>Surgical termination of pregnancy</td>
</tr>
<tr>
<td>ToP Act</td>
<td>Termination of Pregnancy Act 2018 (Qld)</td>
</tr>
<tr>
<td>USS</td>
<td>Ultrasound scan</td>
</tr>
</tbody>
</table>

### Definition of terms

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complex case</td>
<td>May be one in which, in the judgement of the treating health practitioner(s), there are circumstances that complicate the decision-making process and/or care and management of a woman requesting termination of pregnancy. This may include (but is not automatically a requirement of or limited to) issues related to a woman’s medical, social or economic circumstances, capacity to consent, mental health, congenital anomalies, age or gestation of pregnancy at which termination of pregnancy is requested.</td>
</tr>
<tr>
<td>Conscientious objector</td>
<td>A registered health practitioner who refuses to advise or provide or participate in a lawful treatment or procedure because it conflicts with their own personal beliefs, values or moral concerns.</td>
</tr>
<tr>
<td>Healthcare professional</td>
<td>Any healthcare provider involved in the care of a woman requesting termination of pregnancy (i.e. includes social worker, counsellor, hospital liaison officer as well as medical officer and registered nurse or midwife).</td>
</tr>
<tr>
<td>Long acting reversible contraception</td>
<td>At the time of a surgical termination of pregnancy all forms of long acting reversible contraception may be inserted including intrauterine devices (Copper bearing or Levonorgestrel varieties) injections or implants. At the time of medical termination of pregnancy implants and injections may be utilised immediately.</td>
</tr>
<tr>
<td>Live birth</td>
<td>Describes a baby where there are signs of life after birth of the baby is completed regardless of gestation or birthweight. Signs of life may include: beating of the heart, pulsation of the umbilical cord, breath efforts, definite movement of the voluntary muscles, any other evidence of life.</td>
</tr>
<tr>
<td>Multidisciplinary team</td>
<td>Membership of the healthcare team is influenced by the needs of the woman, availability of staff, and other local resourcing issues. May include but is not limited to: nurse, midwife, obstetrician, general practitioner, feto-maternal specialist, social worker, counsellor or hospital liaison officer.</td>
</tr>
<tr>
<td>Obstetrician</td>
<td>Local facilities may, as required, differentiate the roles and responsibilities assigned in this document to an “Obstetrician” according to their specific practitioner group requirements; for example, to gynaecologists, general practitioner obstetricians, specialist obstetricians, consultants, senior registrars and obstetric fellows.</td>
</tr>
<tr>
<td>Performance of a termination</td>
<td>Refer to Section 2.1 Performance of a termination.</td>
</tr>
<tr>
<td>Registered health practitioner</td>
<td>In Australia, health practitioners are registered under the Health Practitioner Regulation National Law. This sets out a framework for the registration and discipline of registered health practitioners and establishes National Boards that set standards, codes and guidelines that registered health practitioners must meet.</td>
</tr>
<tr>
<td>Termination</td>
<td>The Termination of Pregnancy Act 2018 states <em>termination means an intentional termination of a pregnancy in any way, including, for example, by (a) administering a drug; or (b) using an instrument or other thing.</em></td>
</tr>
<tr>
<td>Termination healthcare</td>
<td>In this document <em>termination healthcare</em> refers to the provision of healthcare by a healthcare professional that supports a woman to terminate a pregnancy.</td>
</tr>
<tr>
<td>Vital signs</td>
<td>In this document <em>vital signs</em> includes respiratory rate (RR), blood pressure (BP), heart rate (HR), oxygen saturations (SpO₂), temperature (T) and level of consciousness (LOC).</td>
</tr>
<tr>
<td>Young person</td>
<td>A <em>young person</em> refers to a woman aged less than 18 years.</td>
</tr>
</tbody>
</table>
1 Introduction
‘Termination of pregnancy’ under the *Termination of Pregnancy Act 2018* (Qld)⁴ (the ToP Act) refers to the intentional ending of a pregnancy in any way. The purpose of this guideline is to assist healthcare professionals provide care to women requesting termination of pregnancy (a termination).

1.1 Background
Prior to 3 December 2018, it was unlawful in Queensland under the *Criminal Code Act 1899,* to administer a drug or to perform a surgical or other medical procedure intending to terminate a pregnancy unless such conduct was authorised, excused, or justified by law.

Case law was relied on to provide an excuse from criminal responsibility and justify a termination where a surgical or medical treatment (where the intention was to adversely affect the pregnancy) was provided in good faith, with reasonable care, was to preserve the mother’s life and was reasonable considering all the circumstances of the case.

2 Queensland law
As of 3 December 2018 the ToP Act applies to termination of pregnancy in Queensland.⁴ Termination performed by a registered medical practitioner, is no longer a criminal offence under the Criminal Code; nor is it a criminal offence for a woman to consent to, assist in or perform a termination on herself.⁴ The purposes of the ToP Act are to⁴:
- Enable reasonable and safe access by women to termination
- Regulate the conduct of registered health practitioners in relation to terminations

2.1 Performance of a termination

<table>
<thead>
<tr>
<th>Table 1. Performance of a termination</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aspect</strong></td>
</tr>
<tr>
<td>---</td>
</tr>
</tbody>
</table>
| Context | - The term *performance of a termination* is not further specified or defined in the ToP Act⁴  
  - A consistent clinical interpretation of the term *performance of a termination* is important to identify:  
    - The clinical boundaries that define the start and finish of the *performance of a termination*  
    - Termination healthcare to which conscientious objection may be considered relevant or not  
    - Termination healthcare which a student health practitioner may or may not assist with  
    - Termination healthcare that may be performed by a healthcare professional other than a registered health practitioner |
| Healthcare included in *performance of a termination* | - Expert clinical recommendation is that *performance of a termination* commences when the therapeutic intervention of termination starts and includes:  
  - Dispensing, supplying or administering a termination drug on a medical practitioner’s instruction  
  - Feticide or a surgical procedure of termination performed by a medical practitioner  
  - Feticide or a surgical procedure of termination assisted by a registered healthcare practitioner [refer to Table 3. Assisting with a termination]  
  - At or after 22+1 weeks, determining if a termination should be performed  
  - Refer to Table 2. Medical practitioner responsibilities |
| Healthcare not included in *performance of a termination* | - Expert clinical recommendation is that *performance of a termination* does not include clinical care provided before or after *performance of a termination* including, for example:  
  - Clinical assessment, pre-operative preparation, referral or non-directive counselling, intrapartum or postpartum care after feticide or after administration of a termination drug  
  - Refer to Table 14. Clinical assessment prior to termination  
  - Refer to Table 35. Post-termination care considerations |
2.2 Medical practitioner responsibilities
The legal responsibilities for the medical practitioner in relation to performance of a termination, are specified according to the gestational age of the woman’s pregnancy.4

Table 2. Medical practitioner responsibilities

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Lawful action</th>
</tr>
</thead>
</table>
| **Context** | • Queensland Health considers that:  
 o “Not more than 22 weeks” means less than or equal to 22+0 weeks  
 o “More than 22 weeks” means at or after 22+1 weeks  
 • Use clinical judgement when determining gestational age in individual circumstances |
| **Less than or equal to 22+0 weeks gestation** | • A medical practitioner may perform a termination on a woman upon request4 |
| **At or after 22+1 weeks gestation** | • A medical practitioner may perform a termination if4:  
 o They consider that in all the circumstances, the termination should be performed and  
 o They have consulted with another medical practitioner who also considers that, in all the circumstances, the termination should be performed  
 • Both medical practitioners must consider4:  
 o All relevant medical circumstances  
 o The woman’s current and future physical, psychological and social circumstances  
 o The professional standards and guidelines that apply to the practitioner in relation to the performance of the termination  
 • Consultation5  
 o The second medical practitioner is not required to examine the woman but may wish to do so  
 o Between medical practitioners, consultation in person is not required and may occur by telephone, secure email or video-conference as is required to facilitate access to termination services |

2.3 Registered health practitioners assisting
Assisting in the performance of a termination includes dispensing, supplying or administering a termination drug on a medical practitioner’s instruction.5

Table 3. Assisting with a termination

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Lawful action</th>
</tr>
</thead>
</table>
| **Registered health practitioners** | • The following registered health practitioners may assist a medical practitioner in the performance of a termination5:  
 o Another medical practitioner  
 o Nurse  
 o Midwife  
 o Pharmacist  
 o Aboriginal and Torres Strait Islander health practitioner  
 o Other registered health practitioner prescribed by regulation  
 • Does not apply in relation to a termination the assisting practitioner knows or ought reasonably to know, is being performed by the medical practitioner other than in accordance with the ToP Act4 |
| **Students** | • Student health practitioners are not permitted to assist in the performance of a termination5  
 o A student health practitioner is a person enrolled in an approved program of study or who is undertaking clinical training and is registered as a student with their respective National Board  
 • Refer to Section 2.1 Performance of a termination |
## 2.4 Conscientious objection
Refer to Definition of terms and Section 2.1 Performance of a termination.

Table 4. Conscientious objection

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Lawful action</th>
</tr>
</thead>
</table>
| Relevant to                               | • Registered health practitioners who have a conscientious objection to the performance of a termination and who are asked by a person to:  
  o Perform or assist with the performance of a termination  
  o Make a decision whether a termination should be performed  
  o Advise the person about the performance of termination on a woman                                                                                     |
| Disclosure of objection                   | • Registered health practitioners must disclose their conscientious objection to the requesting person  
  • For example:  
    o If a medical practitioner asks for assistance from a nurse who holds a conscientious objection, the nurse must disclose this to the medical practitioner  
    o If a woman requests performance of a termination from a medical practitioner who holds a conscientious objection, the medical practitioner must disclose this to the woman |
| Referral or transfer of care              | • If a woman requests performance of a termination, a registered health practitioner who has a conscientious objection must refer the woman or transfer her care, without delay, to:  
  o Another registered health practitioner whom they believe can provide the requested termination healthcare and who does not have a conscientious objection OR  
  o A health service provider at which, in the practitioner’s belief, the requested service can be provided by another registered health practitioner who does not have a conscientious objection  
  • Refer or transfer to avoid delays in care provision  
    o Promptly (i.e. during the presentation in which the request is made)  
    o To the nearest/most convenient registered health practitioner or service                                                                   |
| Objection only in certain circumstances   | • Where a registered health practitioner has a conscientious objection only in certain circumstances (e.g. a request beyond X weeks gestation) conscientious objection requirements apply only in that circumstance (i.e. for requests beyond X weeks gestation) |
| Care that is not a matter for conscientious objection | • The conscientious objection provision does not extend to:  
  o Administrative, managerial or other tasks ancillary to the performance of the termination  
  o Hospitals, institutions or services, as the right to conscientiously object is a personal and individual right  
  • Refer to Section 2.1 Performance of a termination                                                                                               |
2.5 Emergency care involving termination

Table 5. Emergency care

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Lawful action</th>
</tr>
</thead>
</table>
| **Medical practitioner** | • In an emergency, a medical practitioner may perform a termination if they consider it is necessary to save the woman’s life or the life of (in a multiple pregnancy) another fetus \(^4\)  
 • If the pregnancy is greater than 22+1 weeks, they may perform the termination:  
   o Without consulting another medical practitioner  
   o Without considering all relevant circumstances |
| **Practitioners assisting** | • In an emergency, a registered health practitioner may assist a medical practitioner performing a termination in the circumstances outlined above \(^4\) |
| **Conscientious objectors** | • Conscientious objection does not limit any duty owed by a registered health practitioner to provide a service in an emergency at any gestation of pregnancy \(^4\)  
 • As for other health emergencies, the medical practitioner is required to consider what assistance they can provide based on their own safety, skills and what other options are available \(^4\) |

2.6 Safe access zones

The purpose of safe access zones is to protect the safety and well-being and respect the privacy and dignity of women and other persons accessing premises where performance of a termination occurs. \(^4\)

Table 6. Safe access zone

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Lawful action</th>
</tr>
</thead>
</table>
| **Safe access zone** | • *Termination services premises* means the premises at which terminations are performed \(^4\)  
   o Does not include a pharmacy  
   • Unless otherwise prescribed by regulation, the prescribed distance is 150 metres from the entrance to the *termination services premises* \(^4\) |
| **Prohibited conduct** | • Conduct in a safe access zone is prohibited if it relates to terminations (or could be reasonably be perceived to be so) and \(^4\):  
   o Would be visible or audible to another person entering or leaving the premises and  
   o Would be reasonably likely to deter a person from entering or leaving the *termination services premises*, requesting or undergoing a termination, or performing or assisting with the performance of a termination  
 • The conduct may be prohibited whether or not another person sees or hears the conduct or is actually deterred \(^4\)  
 • It is an offence to make an audio or visual recording that contains information that could identify a person entering or leaving a termination services premises without the person’s consent, or to publish or distribute a recording without the person’s consent \(^4\) |
### 2.7 Non-compliance with the ToP Act

Table 7. Non-compliance

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Lawful action</th>
</tr>
</thead>
</table>
| **Offences**    | • Termination is considered a health matter  
• No penalty or offence is specified in the ToP Act for a health practitioner’s failure to comply with the requirements of the ToP Act  
  o Including the conscientious objection provision  
• As for other healthcare, the following may apply\(^5,7\):  
  o Professional and legal consequences for non-compliance with the ToP Act  
  o Laws for duty of care, reasonable skill and care  
  o Civil or criminal responsibility for harm that results from a failure to act with reasonable skill and care |
| **Professional conduct** | • Non-compliance with relevant registration and accreditation standards, professional standards (including codes of ethics, codes of conduct and competency standards), policies and guidelines is subject to the same professional and legal consequences as for all other healthcare\(^5\) |

---

\(^5\) Refer to online version, destroy printed copies after use.
### 3 Clinical standards

Where service level capabilities, as defined in the Clinical Services Capability Framework (CSCF), are insufficient to provide termination healthcare, establish referral and transfer systems with other CSCF service level facilities.8

Table 8. Clinical standards

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Considerations</th>
</tr>
</thead>
</table>
| Access to termination healthcare | - Women requesting termination require assessment by a health practitioner who is not a conscientious objector  
  o Refer to Table 4. Conscientious objection  
  - Where termination healthcare is not locally available, support women to access the service, as for any other healthcare not locally available  
  - Provide care to women and families that acknowledges and respects their cultural beliefs and practices  
  - If required, access and provide appropriate interpreter services  
  o Refer to Queensland Clinical Guideline: Standard care9  
  - Provide documented information to consumers, external service providers and support agencies within the local Hospital and Health Service (HHS) on the choices available within the service, and on routes of access to these services  
  - Facilitate access (including via patient travel subsidy scheme, when required) as early as possible and without delay:  
  o Reduce the likelihood of associated health risks  
  o Support maternal preference for a termination procedure that may be impacted by gestational age limitations |
| Referral                          | - Document referral pathways within and between HHSs (e.g. between departments within a facility, between facilities, and between a facility and external agencies or general practitioners (GP))  
  o Consider engagement with statewide external service providers and agencies in the development of referral pathways and mechanisms  
  - Provide documented referral pathways to external service providers, agencies and GPs  
  - Inform healthcare professionals in contact with women seeking termination (e.g. emergency departments, GPs) about referral pathways  
  - If there is a conscientious objection to the performance of a termination, act in accordance with Table 4. Conscientious objection  
  - Where the woman considers but does not proceed to termination, provide information and access to appropriate referral pathways (e.g. access to a social worker, referral for antenatal care)  
  - Refer to the Queensland Health Guide to informed decision making10 |
| Local service delivery           | - Determine the local service delivery mechanisms and administrative reporting requirements within each service  
  - A multidisciplinary and coordinated approach is required to avoid unnecessary delay in the provision of care  
  - Where there are complex issues present (refer to Definition of terms, consider a case review (as for other complex healthcare) to assess the complexities specific to the individual woman |
| Care setting                     | - The most appropriate care setting for termination is dependent on the:  
  o Method of termination chosen  
  o Gestation of the pregnancy11,12  
  o Preferences of the woman and her care provider  
  o The service capabilities of the facility  
  - Ensure there are local arrangements for the safe and sensitive handling, storage and management of fetal tissue |
| Workforce                        | - Educate providers and referrers about the service, the pathways, any service limitations and their professional responsibilities  
  - For healthcare professionals involved in the provision of termination healthcare, provide:  
  o Ongoing training and education11  
  o Access to non-judgemental counselling and debriefing support |
4 Individual case considerations

Termination healthcare is provided in partnership with the woman (and her family, where appropriate) and her healthcare professional. It is led by the woman’s health needs, concerns and choices. Use clinical judgement when determining if all aspects of care are appropriate for the individual woman.

Health practitioners providing termination healthcare are advised to familiarise themselves with their legal responsibilities under the ToP Act. Refer to Section 2 Queensland law.

4.1 Consent

Table 9. Consent

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consent</td>
<td>• Follow usual consent processes and standards including:</td>
</tr>
<tr>
<td></td>
<td>o Assessment of capacity</td>
</tr>
<tr>
<td></td>
<td>o Discussion of available methods of termination</td>
</tr>
<tr>
<td></td>
<td>o Risks and complications of each method of termination</td>
</tr>
<tr>
<td>Capacity to consent</td>
<td>• An adult can give consent (has capacity) if they have:</td>
</tr>
<tr>
<td></td>
<td>o Understand the nature and effect of decisions about the matter</td>
</tr>
<tr>
<td></td>
<td>o Freely and voluntarily makes decisions about the matter and</td>
</tr>
<tr>
<td>Adults who lack capacity</td>
<td>• Termination of a pregnancy of an adult who lacks capacity is considered to be “special healthcare”</td>
</tr>
<tr>
<td></td>
<td>• An attorney, legal guardian or substitute decisionmaker cannot give consent for another person to undergo a termination</td>
</tr>
<tr>
<td></td>
<td>• The Queensland Civil and Administrative Tribunal may consent for an adult who lacks capacity to undergo a termination only if the Tribunal is satisfied that it may be performed by a medical practitioner under the ToP Act</td>
</tr>
<tr>
<td>Young person Gillick</td>
<td>• A young person is considered <em>Gillick</em> competent when they achieve sufficient maturity and intelligence to enable them to understand fully what medical treatment is proposed</td>
</tr>
<tr>
<td>competent</td>
<td>• A <em>Gillick</em> competent young person can consent to medical procedures, in the same way as an autonomous adult with capacity</td>
</tr>
<tr>
<td></td>
<td>• The decision about whether a young person is <em>Gillick</em> competent is a matter for the treating practitioner</td>
</tr>
<tr>
<td></td>
<td>• Consider additional elements of informed consent when obtaining consent from a <em>Gillick</em> competent young person (e.g. the ability to freely and voluntarily make decisions without coercion)</td>
</tr>
<tr>
<td>Young person Gillick</td>
<td>• The law requires that when a competent young person chooses not to include their parents/guardians in consultation, this must be respected, and confidentiality not breached</td>
</tr>
<tr>
<td>competent</td>
<td>• Involve appropriately skilled healthcare professionals for assessment of <em>Gillick</em> competency, psychosocial assessment and family court matters where clinically indicated</td>
</tr>
<tr>
<td></td>
<td>• Refer to Queensland Health: Guide to informed decision making in healthcare</td>
</tr>
<tr>
<td>Young person not Gillick</td>
<td>• For a young person deemed not to have capacity (<em>Gillick</em> competent), the Supreme Court in its <em>pares patriae</em> jurisdiction may authorise the termination</td>
</tr>
<tr>
<td>competent</td>
<td>o The Supreme Court must act in the best interests of the young person</td>
</tr>
<tr>
<td></td>
<td>o A young person’s parents/guardian cannot provide consent to a termination</td>
</tr>
<tr>
<td></td>
<td>• Involve appropriately skilled healthcare professionals for assessment of <em>Gillick</em> competency, psychosocial assessment and family court matters where clinically indicated</td>
</tr>
<tr>
<td></td>
<td>• Escalate these cases to the Executive Director of Medical Services or equivalent (e.g. Medical Superintendent) for urgent attention</td>
</tr>
</tbody>
</table>
4.2 Young person less than 14 years

A young person less than 14 years may be considered *Gillick competent*. Assess individual circumstances. Refer to Table 9. Consent.

Table 10. Young person less than 14 years

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Young person less than 14 years | • Each HHS determines its capability to provide termination healthcare for young people less than 14 years  
• Involve social worker support  
• If not considered *Gillick* competent:  
  o Involve appropriately skilled healthcare professionals for assessment of *Gillick* competency, psychosocial assessment and family court matters  
  o Refer to Table 9. Consent  
• Provide non-judgemental pre-termination psychological counselling by an appropriately qualified healthcare professional  
  o Refer to Section 5.1 Psychological support  
  o Include documented evidence of the pre-termination counselling in the medical record  
• Refer to the Queensland Health: *Guide to informed decision making in healthcare*\(^{10}\) |

4.3 Suspicion of child abuse

Table 11. Suspicion of abuse

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Context\(^{16}\) | • A reportable suspicion is where there is reasonable suspicion that a young person has suffered, is suffering, or is at unacceptable risk of suffering, significant harm caused by physical or sexual abuse; and may not have a parent able and willing to protect them from harm  
• Registered nurses and doctors are mandatory reporters for children where there is reasonable suspicion of harm  
• Any Queensland Health staff member may report a reasonable suspicion of harm |
| Reporting requirements | • Report any reasonable suspicions of abuse and neglect against the young person to Child Safety Services in the Department of Child Safety, Youth and Women\(^{2,8,17}\)  
• Report concerns of sexual activity with suspicion of potential harm, including\(^{16}\):  
  o Non-consensual sexual activity  
  o Occurring between family members  
  o Young person not *Gillick* competent  
  o A significant age gap (5 years or more)  
  o Obvious power differentials  
  o Coercion into sexual activities  
  o Exposure to pornographic material |
4.4 Special circumstances

Table 12. Special circumstances

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Sexual assault           | • Provide termination healthcare on the basis of the woman’s request \(^{11}\)  
                           | • If the pregnancy is reported to have resulted from forced sexual activity, or the woman discloses domestic violence (or fear of violence) discuss with the woman her options for:  
                           |   o Social work support  
                           |   o Alerting authorities (Queensland Police Service)  
                           |   o Relocating, if in continued danger  
                           |   o Routine sexual health checks and treatment (as required)  
                           |   o A medical examination and documentation of findings  
                           |   o Possibility of the products of conception being used for forensic testing to assist legal proceedings  
                           | • Support the woman’s choices for ongoing healthcare and involvement  
                           | • Refer to Queensland Health Policy: *Sexual health and safety guidelines: mental health, alcohol and other drug services* \(^{18}\) |
| Suspected fetal abnormality | • If fetal abnormality suspected, discuss with the woman:  
                           |   o Chromosomal analysis  
                           |   o Histopathology  
                           |   o Autopsy |

4.5 Documentation of decisions

Refer to Queensland Clinical Guideline: *Standard care*.\(^{9}\)

Table 13. Documentation

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Less than or equal to 22+0 weeks                    | • Apply standard documentation principles  
                           | • Refer to Queensland Clinical Guideline: *Standard care* |
| At or after 22+1 weeks and/or complex case           | • Both medical practitioners document:  
                           |   o Clinical opinion about the relevant medical circumstances  
                           |   o Clinical assessment about the woman’s current and future physical, and psychological and social circumstances  
                           |   o Individual clinical assessment of the woman |
## 5 Pre-termination assessment

Offer pre-termination assessment including counselling and psychosocial support services close to home where feasible.19

### Table 14. Clinical assessment prior to termination

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Considerations</th>
</tr>
</thead>
</table>
| Review history                              | • Discuss request for termination services in a non-judgemental and supportive manner  
• Obtain medical, gynaecological, obstetric, and sexual health history\(^{11,12}\) including date of last menstrual period  
• Obtain psycho-social history\(^{20}\) including mental health issues, screening for domestic and family violence and reproductive coercion |
| Clinical exam and investigations            | • Confirm diagnosis, gestational age and location of pregnancy\(^{20}\)  
• Undertake a physical exam as indicated by the history and signs and symptoms including:  
  o Vital signs\(^{11,20,21}\) and body mass index (BMI) if surgical termination  
• Undertake routine antenatal serum screening (if not already screened) including for:  
  o Haemoglobin, blood group and Rh status to identify Rh negative women requiring Rh D immunoglobulin\(^{12,22,23}\)  
  Rubella titre\(^{22,24}\) |
| Ultrasound scan (USS)                       | • USS to confirm intrauterine pregnancy for all women prior to termination  
• If appropriate, ask women about their preference to see/hear USS images and audio |
| Sexual health check                         | • Perform a sexual health check and assess sexually transmitted infection(s) (STI) risk\(^{25}\) including:  
  o Multiple or casual partners  
  o Condom use  
  o History of STI  
  o Symptoms (e.g. discharge, pain on urination, genital rashes)  
• Screen for STI as per local protocol; if no local protocol, consider\(^{25}\)  
  o Chlamydia, gonorrhoea, trichomonas, syphilis, human immunodeficiency virus (HIV)  
• Presumptively treat women for symptomatic STI where follow-up is uncertain/unlikely |
| Pre-termination referral coordination       | • Facilitate timely referral and coordination with other facilities/disciplines/agencies\(^{26}\) for:  
  o Specialist medical assessment (e.g. cardiologist, clinical genetics services, tertiary imaging)  
  o Psychosocial counselling/support  
  β Especially where risk factors are identified (e.g. young person, women with physical or intellectual disabilities, mental illness (past or current), rape or sexual assault, domestic violence (including sexual violence), fertility issues and religious or cultural beliefs/values)  
  o Mental health support/treatment\(^{27}\)  
  o Termination procedure |
| Contraception                               | • Discuss contraceptive options at the time of initial consultation, termination procedure or immediately after\(^{11,26}\)  
• Refer to Table 36. Contraception provision |
| Opportunistic healthcare                    | • Consider opportunistic health screening or advice including:  
  o Cervical screening test  
  o Smoking cessation advice |
| Follow-up                                   | • Arrange follow-up for review/assessment of \(^{11,24,26}\):  
  o Physical recovery  
  o Emotional issues (and referral for counselling as necessary)  
  o Pathology from products of conception including results from fetal autopsy, as indicated  
  o Discussion of ongoing contraception  
• Refer to Table 37. Discharge preparation |
5.1 Psychological support
The decision to terminate a pregnancy may be a difficult, and sometimes, a traumatic process. Consider the woman’s psychological, spiritual and cultural beliefs when providing termination healthcare.

Table 15. Information and counselling

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Considerations</th>
</tr>
</thead>
</table>
| Information    | • Support the decision-making process by providing accurate, impartial and easy to understand information including:
  - Options to continue the pregnancy and parent the child
  - Options to continue the pregnancy and place the child for foster care/adoption/alternative arrangements
  - Documentation of discussions regarding all options for termination (including public and private facility options based on individual needs and circumstances)
  - Post-termination considerations (e.g. contraceptive options and non-judgemental counselling support)
  - Information about local support groups relevant to the circumstances
  - Birth registration requirements [refer to Section 5.4.1 Birth registration] |
| Counselling    | • Offer confidential, non-judgemental support and counselling provided by someone (e.g. social worker, psychologist, counsellor) who:
  - Is appropriately qualified and/or trained
  - Is experienced with the issues surrounding termination
  - Has no vested interest in the pregnancy outcome
  - Where feasible, offer counselling ‘close to home’ to aid the establishment of longer-term counselling support
  - Involve family members as per the woman’s preferences
  - Consider the requirement for formal mental health referral especially if:
    - History of mental illness or suicidal ideations
    - Clinical concern or the woman reports current acute needs |
| Communication  | • Appropriate communication is an important aspect of termination care
  - Use respectful language when referring to the pregnancy
  - Give time for questions to be asked and answered
  - Answer questions honestly and respectfully
  - Use straightforward and simple language
  - Acknowledge and reassure that it is normal to feel a range of emotions (e.g. grief, sadness, relief)
  - Involve the multi-disciplinary team if required
  - Do not:
    - Refer to the pregnancy as ‘products of conception’ or ‘it’
    - Apply judgement for individual motives or reason for termination
    - Imply fault or blame about contraception use/lack of use
    - Try to persuade the woman to change her mind |
| Memory creation| • If appropriate, discuss with the woman (and if she chooses, her family and/or other children) options for ‘memory creation’ which may include:
  - Photographs
  - Hand/footprints
  - Holding or bathing
  - Copies of USS photographs |
5.1.1 Psychological sequelae

Table 16. Psychological healthcare

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>There are significant limitations in the evidence examining the relationships between unplanned pregnancy, termination, birth and mental health(^{32})</td>
</tr>
<tr>
<td></td>
<td>Emotional responses following termination are complex and may change over time</td>
</tr>
<tr>
<td></td>
<td>Risk factors for post-termination psychological problems may include: previous or concurrent psychiatric illness, coercion, increasing length of gestation, ambivalence and lack of social support, poor relationships with others or religious affiliation</td>
</tr>
<tr>
<td></td>
<td>Adverse psychological sequelae may be no more likely following termination than following continuation of the pregnancy(^{33})</td>
</tr>
<tr>
<td></td>
<td>For the majority of mental health outcomes, there is no statistically significant association between termination of pregnancy and mental health problems(^{19,32,34})</td>
</tr>
<tr>
<td></td>
<td>An unwanted pregnancy may lead to an increased risk of mental health problems, or other factors may lead to both an increased risk of unplanned pregnancy and increased risk of mental health problems(^{32-34})</td>
</tr>
<tr>
<td></td>
<td>When a woman has an unwanted pregnancy, rates of mental health problems will be largely unaffected whether she has a termination or goes on to give birth</td>
</tr>
<tr>
<td></td>
<td>Women with a past history of mental health problems may be at increased risk of further mental health issues after an unplanned pregnancy(^{32,33})</td>
</tr>
<tr>
<td>Evidence summary</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consider the need for non-judgemental support and care for all women, and partners, who request a termination</td>
</tr>
<tr>
<td></td>
<td>Discuss with women the importance of seeking support if they experience mental distress/anxiety/health issues or suicidal ideations, particularly if there is a reported history of mental health issues</td>
</tr>
<tr>
<td></td>
<td>Involve members of the multidisciplinary team as appropriate</td>
</tr>
<tr>
<td></td>
<td>Offer the woman a referral to mental health services, where indicated(^{35})</td>
</tr>
</tbody>
</table>
5.2 Method selection

A pregnancy may be terminated using a medical or surgical approach or a combination of the two.\textsuperscript{27} The choice of method is dependent on the woman’s preference, gestational age, local clinician expertise and the service capabilities, and availability of pharmacological agents.\textsuperscript{27}

Table 17. Methods of termination

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Medical termination of pregnancy (MToP) | • Medications are used to induce the termination\textsuperscript{27}  
• May be considered for all gestations of pregnancy  
• Mifepristone in combination with misoprostol (or misoprostol alone) are the recommended regimens for MToP  
  o MS-2 Step is recommended for gestations 63 days or less  
  o Refer to Section 6.5 MToP at 63 days gestation or less |
| Surgical termination of pregnancy (SToP) | • Surgical curettage is generally suitable up to 12 weeks gestation\textsuperscript{20}  
  o Between 12–16 weeks (or greater) gestation, performed only by an experienced practitioner\textsuperscript{20}  
• Anaesthesia depends on service capabilities\textsuperscript{8}  
• Refer to Section 7 Surgical termination |
| Feticide                    | • Provided by a trained specialist  
• Usually for gestations greater than 22+1 weeks\textsuperscript{20,26,36} as is clinically appropriate  
• Refer the woman to the closest service with the capability to perform the procedure\textsuperscript{8}  
• Post feticide, a woman may be transferred to another facility for birth if\textsuperscript{8}:  
  o Considered clinically safe  
  o There is a robust referral process  
  o There is comprehensive documentation  
• Involve the woman and the receiving hospital in decisions about transfer |
| Selective reduction/selective feticide | • If selective reduction or selective feticide is required in multiple pregnancies, consider the woman’s individual circumstances on a case by case basis\textsuperscript{5} |

5.2.1 Other considerations for method selection

Table 18. Considerations for selection

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Service capability</td>
<td>• If there is limited capability for a preferred method, refer promptly to another service or provider\textsuperscript{8}</td>
</tr>
</tbody>
</table>
| Risks and complications     | • Discuss the complications and risks associated with the differing methods of termination in a way the woman can understand  
• Advise of the overall safety of the procedures\textsuperscript{12} |
| Acceptability of method     | • Satisfaction with MToP and SToP reported as comparable\textsuperscript{37,38}  
• Support the woman to make the decision that is best for her circumstances and preferences  
• Consider additional psychological support for women at greater than 16 weeks gestation who receive inpatient care within the maternity services |
5.3 MToP and SToP risks and complications

Complications and risks associated with termination of pregnancy are rare when performed by qualified medical practitioners. Serious complications are rare and morbidity is less common with terminations than with pregnancies that are carried to term.

Table 19. Risks and complications

<table>
<thead>
<tr>
<th>Complication</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retained products of conception</td>
<td>• Uncommon following SToP&lt;br&gt;• Requirement for surgical evacuation of retained products increased following MToP³⁹</td>
</tr>
<tr>
<td>Infection</td>
<td>• Risk reduced if: o Prophylactic antibiotics prior to SToP¹²&lt;br&gt;β Refer to Section 7.3 Surgical curettage&lt;br&gt;o Lower genital tract infection has been excluded</td>
</tr>
<tr>
<td>Cervical trauma</td>
<td>• Rates vary during SToP; risk of damage to the external cervical os at the time of surgical termination is no greater than 1 in 100¹²&lt;br&gt;• Decreased risk with: o Experienced clinician¹²&lt;br&gt;o Use of preoperative cervical priming²⁴&lt;br&gt;o Earlier gestations</td>
</tr>
<tr>
<td>Haemorrhage</td>
<td>• Risk is lower at earlier gestations o First trimester: less than 1 in 1000 terminations³¹&lt;br&gt;o Greater than 20 weeks: 4 in 1000 terminations³¹&lt;br&gt;• May be more common following MToP (bleeding may persist up to 45 days) but evidence is not conclusive¹²,²⁰</td>
</tr>
<tr>
<td>Uterine perforation</td>
<td>• Risk at the time of surgical termination is 1–4 in 1000³¹&lt;br&gt;• Decreased risk of uterine perforation associated with: o Experienced clinician&lt;br&gt;o Use of pre-operative cervical priming²⁴,³¹&lt;br&gt;o Earlier gestations</td>
</tr>
<tr>
<td>Uterine rupture</td>
<td>• Uterine rupture has been rarely reported in association with mid-trimester MToPs⁴⁰&lt;br&gt;• More frequently associated with later gestational ages and previous uterine scar²⁴&lt;br&gt;• Risk is less than 1 in 1000 terminations³¹</td>
</tr>
<tr>
<td>Failure to achieve termination of the pregnancy</td>
<td>• All methods of first trimester termination carry a small risk of failure to terminate o Approximately 1–2 in 100 pregnancies across both surgical and medical procedures³¹&lt;br&gt;• More likely following early rather than late termination of pregnancy&lt;br&gt;• Failed termination of pregnancy while uncommon may lead to fetal anomalies if the pregnancy persists³¹</td>
</tr>
<tr>
<td>Future pregnancies</td>
<td>• There are no proven associations between termination of pregnancy and subsequent ectopic pregnancy, placenta praevia or infertility³¹</td>
</tr>
<tr>
<td>Surgery, anaesthetic or sedation</td>
<td>• Standard risks common to all surgical procedures requiring anaesthetic or sedation&lt;br&gt;• Consider: o Individual circumstances and general health of the woman&lt;br&gt;o Service capabilities</td>
</tr>
</tbody>
</table>
5.4 Fetal considerations
Provide information to women (as appropriate to the clinical circumstances) about birth and death registration requirements and the management of fetal remains.

5.4.1 Birth registration

Table 20. Registration requirements

<table>
<thead>
<tr>
<th>Gestation/Birth weight</th>
<th>Signs of life</th>
<th>Requirement</th>
</tr>
</thead>
</table>
| Less than 20 weeks AND less than 400 grams | Not live born | • Birth registration not required  
• Death certificate not required  
• Burial/cremation not required |
| Less than 20 weeks AND less than 400 grams | Live born | • Birth registration required  
• Death certificate required  
• Burial/cremation required |
| Greater than 20 weeks OR more than 400 grams | Not live born OR Live born | • Birth registration required  
• Death certificate required  
• Burial/cremation required |

5.4.2 Transport and management of fetal remains

Table 21. Management of fetal remains/tissue

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Lawful disposal | • Where birth and death registration is required, burial or cremation of fetal remains is required within a cemetery or at a crematorium\textsuperscript{41}  
• Where birth and death registration is not required:  
o Many local councils regulate how fetal remains may be disposed of outside of a cemetery or crematorium  
o Hospital facilities may be permitted to dispose of fetal remains by incineration or chemical disinfection\textsuperscript{42} |
| Requests to take fetal remains home/overseas | • Fetal remains that do not legally require burial or cremation may be released to the woman for private disposal provided that\textsuperscript{42,43}:  
o There is no risk of transmission of notifiable conditions  
o The woman has been informed how the fetal remains may be lawfully disposed  
• Establish local protocols to support requests to take fetal remains home (e.g. use of sensitive transport containers)  
• Provide information:  
o About safe and legal disposal  
o About safe management of fetal remains, including infection control\textsuperscript{42}  
o About community queries regarding fetal remains that are to be transported within Australia or overseas |
| Individual preferences | • Recognise that a woman may wish to make her own arrangements for disposal  
• Respect cultural and/or religious beliefs\textsuperscript{44}  
• Advise women:  
o Of the options for lawful disposal  
o Of local council regulations for disposal on private property  
o Funeral services may assist with burial/cremation where birth registration is not required, and no death certificate has been issued  
o Memorial services may be offered at the facility  
• Consider the condition of the fetal remains and inform the woman appropriately  
• Offer social worker support  
• For births less than 20 weeks gestation, or less than 400 grams (i.e. not requiring registration), offer information on purchasing a commemorative certificate from Queensland Registry of Births Deaths Marriages |
5.4.3 Other fetal considerations

Table 22. Fetal considerations

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **Live birth**                | • Provide individualised and holistic care to women according to circumstances  
                                 |   • If appropriate, discuss the potential for live birth with the woman  
                                 |   o Refer to Definition of terms  
                                 |   • Establish local procedures for the management of live birth  
                                 |   • Offer counselling and support services to women, partners and healthcare professionals involved with care of a live born fetus  
                                 |   • If a live birth occurs\(^{45}\):  
                                 |   o Handle baby gently and carefully and wrap to provide warmth  
                                 |   o Offer opportunities and support the family's wishes to engage in care provision (e.g. cuddling/holding)  
                                 |   o Do not provide life sustaining treatment (e.g. gastric tubes, IV lines, oxygen therapy)  
                                 |   o Provide sensitive emotional support and reassurance to parents throughout the process and afterwards  
                                 |   o Document date and time end of life occurs  |
| **Fetal autopsy**             | • Offer fetal autopsy if clinically indicated (e.g. if fetal abnormality)  
                                 |   • Refer to Queensland Clinical Guideline: *Stillbirth care*\(^{46}\)  |
| **Gestations greater than 16 weeks** | • Discuss with women, as appropriate to clinical circumstance:  
                                 |   o Possibility for live birth  
                                 |   o Options for memory creation  
                                 |   o Autopsy, if indicated  
                                 |   o Birth registration requirements  
                                 |   o Donation of breast milk to milk banks (where appropriate) or lactation suppression  
                                 |   o Involve social workers (e.g. for support, discussion of any costs, funeral arrangements)  
                                 |   o Offer information about community services (e.g. Harrison's Little Wings, Children by Choice, Mental Health Access Line, Pregnancy Counselling link)  |
6 Medical termination
Medical methods of termination are safe and effective. Where local protocols are not well established or do not exist, suggested regimens are provided in the following sections.

6.1 Practitioner requirements
Australian healthcare professionals must register with MS Health online to become licensed prescribers or dispensers of MS-2 Step (mifepristone, misoprostol) and/or mifepristone.47,48 MS-2 Step, mifepristone, and misoprostol are conditionally approved for use by Queensland Health as per the list of approved medicines (LAM).49

6.2 MToP precautions

Table 23. Precautions for medical termination

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contraindications for MToP</strong></td>
<td>• Known hypersensitivity or allergy to prostaglandins or any component of the product50</td>
</tr>
<tr>
<td></td>
<td>• Suspected or confirmed ectopic pregnancy50</td>
</tr>
<tr>
<td></td>
<td>• Gestational trophoblastic disease50</td>
</tr>
<tr>
<td></td>
<td>• Intrauterine device (remove prior to termination)50</td>
</tr>
<tr>
<td></td>
<td>• Obstructive cervical lesions (e.g. fibroids)</td>
</tr>
<tr>
<td></td>
<td>• High suspicion of placenta accreta</td>
</tr>
<tr>
<td><strong>Cautions for MToP</strong></td>
<td>• If cardiovascular disease, monitor cardiovascular status as prostaglandins may cause transient blood pressure changes51</td>
</tr>
<tr>
<td></td>
<td>• If high risk of uterine rupture50</td>
</tr>
<tr>
<td></td>
<td>• Consider individual circumstances52</td>
</tr>
<tr>
<td></td>
<td>• May not be suitable with history of caesarean section (CS), multiple pregnancies or uterine abnormalities53</td>
</tr>
<tr>
<td></td>
<td>• If previous traumatic pregnancy loss (e.g. miscarriage), counsel women on blood loss associated with MToP54</td>
</tr>
<tr>
<td></td>
<td>• Vaginal bleeding is heavier with MToP compared with SToP and may be comparable to a miscarriage</td>
</tr>
<tr>
<td></td>
<td>• If breastfeeding: MToP medications may cause diarrhoea in the child55</td>
</tr>
<tr>
<td><strong>Contraindications to mifepristone</strong></td>
<td>• Chronic adrenal failure</td>
</tr>
<tr>
<td></td>
<td>• Concurrent long-term corticosteroid therapy</td>
</tr>
<tr>
<td></td>
<td>• Known or suspected haemorrhagic disorders or treatment with anti-coagulants56</td>
</tr>
</tbody>
</table>

6.3 MToP in the outpatient setting

Table 24. Healthcare setting

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Context</strong></td>
<td>• To identify the most appropriate setting for MToP consider:</td>
</tr>
<tr>
<td></td>
<td>• Local service capability</td>
</tr>
<tr>
<td></td>
<td>• Individual circumstances</td>
</tr>
<tr>
<td></td>
<td>• Woman’s preferences</td>
</tr>
<tr>
<td></td>
<td>• Geographic distances to be travelled if emergency care is required</td>
</tr>
<tr>
<td><strong>Suggested criteria</strong></td>
<td>• If no local criteria established, outpatient care may be suitable for women who meet all of the following:</td>
</tr>
<tr>
<td></td>
<td>• Are less than or equal to 9 weeks gestation</td>
</tr>
<tr>
<td></td>
<td>• Are accompanied by a support person, who has been adequately informed about what to expect, until the termination is complete28</td>
</tr>
<tr>
<td></td>
<td>• Have immediate access to transport and telephone</td>
</tr>
<tr>
<td></td>
<td>• Can communicate by telephone (e.g. have an interpreter available if required)</td>
</tr>
<tr>
<td></td>
<td>• Have the capacity to understand and follow instructions</td>
</tr>
<tr>
<td></td>
<td>• Can access a 24 hour emergency healthcare facility with minimal delay</td>
</tr>
<tr>
<td></td>
<td>• Have follow-up arrangements in place</td>
</tr>
</tbody>
</table>
### 6.4 MToP pre-dosage care

Table 25. MToP pre-dosage care

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Clinical care                 | • Perform a pre-termination assessment  
  o Pre-termination assessment  
  • Obtain informed consent  
  o Refer to Section 4.1 Consent  
  • Exclude contraindications and review cautions  
  o Refer to Section 6.2 MToP precautions  
  • Consider the need for Rh D immunoglobulin prophylaxis  
  o Refer to Table 35. Post-termination care considerations |
| Communication                 | • Provide information about:  
  o The process (e.g. duration, timing of medication, symptoms, passage of tissue)  
  o When to seek emergency care  
  • If indicated, discuss collection of products of conception for examination |
| Medication side effects       | • Provide information about possible medication side effects  
  • Adverse events for combined use of mifepristone and misoprostol are dose dependent and increase with gestational age57,58  
  • Common side effects include20,21,52:  
  o Prolonged vaginal bleeding  
  o Nausea, vomiting, diarrhoea  
  o Headache  
  o Abnormal thermoregulation (e.g. hot flushes, low grade temperature)  
  o Abdominal pain and cramps  
  • If woman is breastfeeding, refer to product information |
| Follow-up                     | • Confirm follow-up arrangements  
  • Discuss options and preference for contraception  
  • Refer to Section 8 MToP and SToP post-termination care |
6.5 MToP at 63 days gestation or less
MS-2 Step composite pack is suitable for termination at 63 days or less gestation (9+0 weeks).48

Table 26. MS-2 Step for MToP

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **MS-2 Step composite pack**<sup>39</sup> | - Consists of:  
  o Mifepristone 200 mg (1 tablet containing 200 mg)  
  o Misoprostol 800 micrograms (4 tablets, each tablet containing 200 micrograms) |
| **Efficacy** | - For women less than 49 days gestational age<sup>39</sup>:  
  o Efficacy 97.3%  
  o Incomplete termination requiring aspiration 2.3%  
  o Rate of ongoing pregnancy 0.3%  
  - For women with a gestational age between 49 to 63 days:  
    o Efficacy 95.2%  
    o Incomplete termination requiring aspiration 4.8%  
    o Rate of ongoing pregnancy 0.6% |
| **Pre-dosage care** | - Refer to Table 25. MToP pre-dosage care  
  - Provide written information about misoprostol medication self-administration<sup>52</sup>  
  - Supply a prescription for analgesia and antiemetics |
| **Dose**<sup>48</sup> | **Initial dose:**  
  - Mifepristone 200 mg oral  
  - If Rh negative, recommend Rh D Immunoglobulin<sup>22</sup>  
    o Refer to Table 35. Post-termination care considerations  
  **Subsequent dose:**  
  - 36–48 hours after mifepristone  
    o Misoprostol 800 micrograms buccal or sublingual |
| **Follow-up** | - Follow-up at 14–21 days as per local protocols  
  - Confirm expulsion complete<sup>39,55</sup>:  
    o Clinical examination (vital signs, abdominal cramping, pain, history of tissue passed)  
    o Serum β-hCG assay, or urine pregnancy test, if indicated  
    o USS if indicated  
    o No ongoing persistent vaginal bleeding  
  - Referral for surgical procedure or other follow-up if required  
  - Refer to Table 37. Discharge preparation |

*Caution: refer to the Australian product information for complete drug information*
6.6 MToP after 63 days gestation

A combination regimen with a prostaglandin analogue is more effective than use of either medication as a single analogue agent.39

6.6.1 Care during MToP

Table 27. MToP considerations after 63 days gestation

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cautions</td>
<td>• Seek expert advice from a higher level service as required&lt;br&gt;• Fetocide required for gestations greater than 22 weeks</td>
</tr>
<tr>
<td>Pre-care</td>
<td>• Refer to Table 25. MToP pre-dosage care&lt;br&gt;• Baseline vital signs, vaginal loss, pain prior to commencement&lt;br&gt;• IV access is recommended&lt;br&gt;• If Rh negative, recommend Rh D Immunoglobulin22&lt;br&gt;• Full blood count (FBC), group and hold as clinically indicated</td>
</tr>
<tr>
<td>Inpatient clinical care</td>
<td>• Offer analgesia&lt;br&gt;• Offer antiemetics if required&lt;br&gt;• Vaginal examination as clinically indicated&lt;br&gt;• Bed rest for 30 minutes after each dose but may mobilise freely at other times&lt;br&gt;• Consider oxytocin IV at time of birth&lt;br&gt;• If the placenta is not spontaneously delivered within 60 minutes of the fetus (or earlier if excessive bleeding occurs) consider operative removal</td>
</tr>
<tr>
<td>Observations</td>
<td>• 30–60 minutes after initial dose of misoprostol and after each subsequent dose&lt;br&gt;  ○ Vital signs vaginal loss, contractions, assess pain</td>
</tr>
</tbody>
</table>

6.6.2 MToP regimen for women at risk of uterine rupture

Table 28. MToP with risk of uterine rupture

<table>
<thead>
<tr>
<th>Risk of uterine rupture or with previous uterine surgery</th>
<th>Cautions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Seek expert advice from a higher level service as required&lt;br&gt;• Fetocide required for gestations greater than 22 weeks&lt;br&gt;• Consider IV access and monitor women closely for evidence of scar complications</td>
</tr>
<tr>
<td>Less than 34+0 weeks</td>
<td>• Day 1: mifepristone 200 mg oral39&lt;br&gt;• Day 2: 36–48 hours after mifepristone&lt;br&gt;  ○ Misoprostol 200 micrograms inserted into the posterior fornix of the vagina&lt;br&gt;  ○ If undelivered at 4 hours after initial dose, then misoprostol 200 micrograms inserted into the posterior fornix of the vagina every 4 hours for 4 doses (may also be given sublingual or buccal)&lt;br&gt;• If undelivered at 24 hours after initial dose, then commence misoprostol 400 micrograms inserted into the posterior fornix of the vagina every 6 hours for a maximum of 4 further doses&lt;br&gt;• If undelivered at 48 hours after initial dose, then review by an obstetrician is indicated. Options may include:&lt;br&gt;  ○ Continue with misoprostol 400 micrograms 6 hourly or&lt;br&gt;  ○ Rest day then recommence or&lt;br&gt;  ○ IV oxytocin is most effective if some effacement and dilation has occurred or&lt;br&gt;  ○ Surgical delivery</td>
</tr>
<tr>
<td>34+0 weeks or more</td>
<td>• Transcervical catheter&lt;br&gt;• Oxytocin infusion and artificial rupture of membranes&lt;br&gt;• Avoid misoprostol or dinoprostone</td>
</tr>
</tbody>
</table>

Refer to an Australian pharmacopoeia for complete drug information

Refer to online version, destroy printed copies after use
6.6.3 MToP regimen for women not known to be at risk of uterine rupture

Table 29. MToP with no known risk of uterine rupture

<table>
<thead>
<tr>
<th>Follow protocol according to gestational age</th>
<th>9+0 to 12+6 weeks</th>
<th>13+0 to 24+6 weeks</th>
<th>25+0 to 33+6 weeks</th>
<th>34+0 weeks or more</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Day 1: mifepristone 200 mg oral³⁹</td>
<td>• Day 1: mifepristone 200 mg oral³⁹</td>
<td>• Day 1: mifepristone 200 mg oral³⁹</td>
<td>• Pre-induction:</td>
</tr>
<tr>
<td></td>
<td>• Day 2: 36–48 hours after mifepristone²⁰</td>
<td>• Day 2: 36–48 hours after mifepristone²⁰</td>
<td>• Day 2: 36–48 hours after mifepristone²⁰</td>
<td>• Dinoprostone or transcervical catheter</td>
</tr>
<tr>
<td></td>
<td>o Misoprostol 800 micrograms vaginal, sublingual or buccal</td>
<td>o Misoprostol 400 micrograms vaginal or sublingual</td>
<td>o Misoprostol 400 micrograms vaginal or sublingual</td>
<td>o Induction</td>
</tr>
<tr>
<td></td>
<td>o Followed by misoprostol 400 micrograms vaginal or sublingual every three hours up to a maximum of four further doses</td>
<td>o Followed by misoprostol 400 micrograms vaginal or sublingual every three hours up to a maximum of four further doses</td>
<td>o Followed by misoprostol 400 micrograms vaginal or sublingual every three hours up to a maximum of four further doses</td>
<td>o Misoprostol 50–100 micrograms sublingually or per vagina 3–6 hourly for five doses over 24 hours</td>
</tr>
<tr>
<td></td>
<td>• If fetus undelivered, consider additional misoprostol dose or surgical procedure</td>
<td></td>
<td></td>
<td>o Oxytocin infusion and consider artificial rupture of membranes after labour established</td>
</tr>
</tbody>
</table>

Caution: refer to the Australian product information for complete drug information.
7 Surgical termination

Surgical curettage is generally suitable for gestations of pregnancy up to 14 weeks. Surgical procedures for pregnancies greater than 14–16 weeks gestation require a clinician with the relevant training and experience.

7.1 SToP pre-procedure care

Table 30. SToP pre-procedure care

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical care</td>
<td>• Perform a pre-termination assessment</td>
</tr>
<tr>
<td></td>
<td>o Pre-termination assessment</td>
</tr>
<tr>
<td></td>
<td>• Obtain informed consent</td>
</tr>
<tr>
<td></td>
<td>o Refer to Section 4.1 Consent</td>
</tr>
<tr>
<td></td>
<td>• Consider the need for Rh D immunoglobulin</td>
</tr>
<tr>
<td></td>
<td>o Refer to Table 35. Post-termination care considerations</td>
</tr>
<tr>
<td></td>
<td>• Consider the need for cervical priming</td>
</tr>
<tr>
<td></td>
<td>o Refer to Table 31. Cervical priming</td>
</tr>
<tr>
<td>Communication</td>
<td>• Provide information about:</td>
</tr>
<tr>
<td></td>
<td>o The termination process</td>
</tr>
<tr>
<td></td>
<td>o What symptoms to expect post procedure including bleeding and pain</td>
</tr>
<tr>
<td></td>
<td>o Refer to Table 15. Information and counselling</td>
</tr>
</tbody>
</table>

7.2 Cervical priming for SToP

Table 31. Cervical priming for SToP

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rationale</td>
<td>• Cervical preparation decreases the length of SToP procedure</td>
</tr>
<tr>
<td></td>
<td>• May also:20,21:</td>
</tr>
<tr>
<td></td>
<td>o Reduce complications of uterine perforation and cervical injury</td>
</tr>
<tr>
<td></td>
<td>o Make the procedure easier to perform</td>
</tr>
<tr>
<td></td>
<td>o Make the procedure more comfortable for the woman</td>
</tr>
<tr>
<td>Options</td>
<td>• Pharmacological agents</td>
</tr>
<tr>
<td></td>
<td>o Mifepristone and misoprostol</td>
</tr>
<tr>
<td></td>
<td>o Misoprostol alone</td>
</tr>
<tr>
<td>Recommendation</td>
<td>• Recommended:</td>
</tr>
<tr>
<td></td>
<td>o For women less than 18 years of age</td>
</tr>
<tr>
<td></td>
<td>o For nulliparous women</td>
</tr>
<tr>
<td></td>
<td>o After 12–14 weeks gestation21 (although may be considered at any gestational age)</td>
</tr>
</tbody>
</table>

Caution: refer to the Australian product information for complete drug information

7.2.1 Misoprostol prior to SToP

Table 32. Misoprostol alone for cervical priming prior to surgical termination

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Precautions</td>
<td>• Refer to Table 23. Precautions for medical termination</td>
</tr>
<tr>
<td>Dosage</td>
<td>• 3–4 hours prior to surgery20</td>
</tr>
<tr>
<td></td>
<td>• 400 micrograms inserted into the posterior fornix of the vagina</td>
</tr>
<tr>
<td></td>
<td>OR</td>
</tr>
<tr>
<td></td>
<td>• 2–3 hours prior to surgery20</td>
</tr>
<tr>
<td></td>
<td>• 400 micrograms oral, sublingual or buccal</td>
</tr>
</tbody>
</table>

Caution: refer to the Australian product information for complete drug information
7.2.2 Mifepristone and misoprostol prior to SToP

Table 33. Mifepristone and misoprostol for cervical priming prior to surgical termination

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Precautions</td>
<td>• Refer to Table 23. Precautions for medical termination</td>
</tr>
<tr>
<td>Day 1: Pre-dose care</td>
<td>• May occur as an outpatient</td>
</tr>
<tr>
<td></td>
<td>• Baseline maternal vital signs</td>
</tr>
<tr>
<td>Day 1: Dosage (24–48 hours prior to procedure)</td>
<td>• Mifepristone 200 mg oral&lt;sup&gt;20&lt;/sup&gt;</td>
</tr>
<tr>
<td>Day 1: Post-dose care</td>
<td>• Observe for one hour post mifepristone administration in case of nausea and vomiting</td>
</tr>
</tbody>
</table>
| Day 2 (Day of procedure)     | • If less than 14 weeks gestation<sup>20</sup>:  
  o Misoprostol 400 micrograms sublingual 2–3 hours prior to procedure  
  o OR  
  o Misoprostol 400 micrograms vaginally 3–4 hours prior to the procedure                                                                 |
|                               | • If greater than 14 weeks gestation<sup>20</sup>:  
  o Misoprostol 400 micrograms vaginally 3–4 hours prior to procedure                                                                         |

*Caution: refer to the Australian product information for complete drug information

7.3 Surgical curettage

Table 34. Considerations for surgical termination

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Prophylactic antibiotics      | • Intra or perioperative prophylactic antibiotics recommended<sup>20,21,24</sup>  
  • In the absence of local protocols consider:  
  o Doxycycline 400 mg orally, with food, 10–12 hour prior to procedure OR  
  o Doxycycline 100 mg orally 60 minutes prior to procedure THEN 200 mg orally 90 minutes after the procedure<sup>62</sup>  
  o If medication allergy refer to Therapeutic Guidelines for alternate antibiotic regime<sup>62</sup>  
  o Opportunistic healthcare including cervico-vaginal screening for STI<sup>§</sup> Refer to Table 14. Clinical assessment prior to termination |
| Anaesthesia                   | • Method may depend on service capabilities and the woman’s choice  
  • May be performed with or without oral or intravenous tranquilliser  
  • Analgesics, local anaesthesia and/or mild sedation are usually sufficient                                                                 |
| Oxytotic agents               | • May decrease the risks of haemorrhage but not routinely recommended for vacuum aspiration                                                   |
| USS                           | • May be used to check completeness                                                                                                        |
|                               | • Routine use not required at less than 12 weeks<sup>33</sup>                                                                                |
| Examination of tissue         | • Examination of the products of conception by the surgeon may assist with recognition of gestational trophoblast<sup>63</sup>  
  • Histopathology if clinically indicated<sup>20</sup>  
  • Refer to Table 35. Post-termination care considerations                                                                                  |
| Side effects                  | • Pain: analgesia is usually required (e.g. non-steroidal anti-inflammatory drugs)  
  • Bleeding: expected duration 5–18 days<sup>27</sup>  
  • Nausea: usually related to prostaglandins or anaesthetic drugs<sup>27</sup>                                                              |
| Risks and complications       | • Serious complications are rare<sup>27</sup>  
  • Risk rises with operator inexperience and gestational age<sup>21</sup>                                                                       |
| Follow-up                     | • Recommend follow up (e.g. GP, telephone/video contact, face to face) to discuss:  
  o Bleeding  
  o Psychological well-being  
  o Contraception [refer to Table 36. Contraception provision]  
  • Refer to Section 8.2 Discharge preparation and follow-up                                                                                   |

*Caution: refer to the Australian product information for complete drug information
8 MToP and SToP post-termination care

Most serious complications are detectable in the immediate post-procedure period. Refer to Table 19. Risks and complications. Appropriate and accessible follow-up care is essential.\textsuperscript{21}

Table 35. Post-termination care considerations

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Post-procedural care | • Provide routine post-procedural care including assessment of vital signs, consciousness and observation of vaginal loss  
                                • Where possible provide inpatient care that is not within a maternity service environment                                                                                           |
| Rh prophylaxis*      | • Recommend Rh D immunoglobulin to all Rh D negative women within 72 hours of termination (medical or surgical)\textsuperscript{21-23} (unless the fetus is known to be Rh negative)  
                                o Gestations 1–12+6 weeks—250 IU Rh D immunoglobulin via intramuscular (IM) injection  
                                o Gestations 13+0 weeks or more—625 IU Rh D immunoglobulin via intramuscular (IM) injection  
                                • If greater than 20 weeks gestation, recommend quantification of feto-maternal haemorrhage (FMH)\textsuperscript{22}  
                                o If FMH estimated at 6 mL or more, recommend additional Rh D immunoglobulin                                                                                                         |
| Analgesia            | • Individually determine analgesia requirements after surgical termination or during and after MToP as requirements vary  
                                • Offer medication for pain management\textsuperscript{11} (paracetamol and/or ibuprofen often effective)  
                                • Advise women that severe pain may be indicative of uterine perforation or clot retention\textsuperscript{11}  
                                o Seek advice if analgesia provided unable to manage pain effectively                                                                                                                     |
| Histopathology       | • If clinically indicated or suspicion of fetal abnormality, consider histopathological examination and chromosomal analysis (microarray) of tissue obtained during termination procedures |

*Caution: refer to the Australian product information for complete drug information

8.1 Contraception

Australia has a relatively high rate of unintended pregnancy (19.7 per 1000 women aged 15–44 years).\textsuperscript{64} Australia ranks amongst the highest countries for termination of pregnancy in the developed world with 1 in 4 women undergoing a termination procedure.\textsuperscript{65,66}

Table 36. Contraception provision

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Context                             | • Prevention of unwanted future pregnancies is an important part of the provision of termination healthcare  
                                • Women who do not attend follow-up appointments for contraception are at higher risk of unintended pregnancy than women who have contraception provided at time of termination\textsuperscript{67} |
| Information                         | • Ideally, commence discussions about contraception during first contact  
                                • Discuss options based on woman’s preference including short and long acting methods  
                                • Provide information on side effects, benefits and failure rates of methods  
                                • Offer information on benefits of condom use in preventing STI\textsuperscript{25}  
                                • If contraception declined, offer information (as appropriate to the circumstances) about:  
                                o Types of contraception available  
                                o Accessing local services for contraceptive advice or support  
                                o The importance of prevention of future unwanted pregnancies                                                                                                                  |
| Long acting reversible contraception | • Significantly less likely to result in unintended pregnancy than short-acting user-dependent methods, such as the oral contraceptive pill\textsuperscript{66,67}  
                                • May be inserted, during a SToP, or immediately post MToP or SToP\textsuperscript{20}  
                                • Provide information on what to expect after insertion                                                                                                 |

Refer to online version, destroy printed copies after use
### 8.2 Discharge preparation and follow-up

#### Table 37. Discharge preparation

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **Counselling and support** | • Promote continuity of care to facilitate the development of longer-term support opportunities  
• Provide information on accessing support agencies/organisations appropriate to individual circumstances (e.g. GP, grief counselling or support groups)  
• Offer referral for counselling, especially where risk factors for long-term post-termination distress are evident (e.g. ambivalence before the termination, lack of a supportive partner, psychiatric history or membership of a religious or cultural group where termination is not an option)  
• Offer information and assistance as appropriate regarding birth registration and funeral arrangements  
  o Refer to Table 20. Registration requirements  
  o Refer to Table 15. Information and counselling |
| **Lactation**           | • If appropriate, discuss the possibility of lactation including  
  o Suppression (pharmacological and comfort measures)  
  o Donation of breast milk to milk banks  
  o Emotional response to lactation |
| **Risk of infection**   | • To reduce risk of infection, recommend (until bleeding ceased) avoiding:  
  o Vaginal intercourse  
  o Insertion of tampons or other products into the vagina  
  o Bathing or swimming |
| **Subsequent pregnancy**| • If there are no physical, psychological, health related or other barriers after a termination, conception can be attempted immediately following the termination  
• If appropriate offer information about pre-conceptual care (e.g. folic acid, smoking cessation, rubella immunisation if required) |
| **Discharge**           | • Determine timing of discharge on an individual basis  
• Consider routine discharge criteria (e.g. vital signs, recovery from effects of sedation/anaesthesia)  
• Supply a prescription for analgesia and antiemetics  
• Provide written information regarding post-procedure symptoms and accessing emergency care  
  o Refer to Queensland Clinical Guidelines: *Patient information on post termination care*  
• Provide a confidential letter to the woman that gives sufficient information about the procedure to allow another practitioner elsewhere to deal with any complications (particularly for women living in rural and remote locations)  
• Seek consent for discharge letter distribution (e.g. to GP) |
| **Follow-up**           | • After MToP, recommend follow-up within 14–21 days (e.g. GP, telephone/video contact, face to face)  
• After SToP, offer follow-up based on individual circumstances (e.g. if procedure complicated or additional support required)  
• If appropriate  
  o Schedule follow-up to discuss pathology results, especially where there was histopathology/autopsy for fetal abnormality  
  o Recommend referral to medical specialists (e.g. clinical genetics services)  
  o Review emotional wellbeing of woman and family  
• Where follow up is difficult, or uncertain encourage woman to seek support from GP or local health service for  
  o Passage of tissue  
  o Ongoing bleeding and/or pain  
  o Contraception |
References

34. Biggs MA, Upadhyay UD, McCulloch CE, Foster DG. Women’s mental health and well-being 5 years after receiving or being denied an abortion: a prospective, longitudinal cohort study. JAMA Psychiatry 2017;74(2):169-78.
Acknowledgements

The Queensland Clinical Guidelines gratefully acknowledge the contribution of Queensland clinicians and other stakeholders who participated throughout the guideline development process.

Working Party Clinical Lead
Associate Professor Rebecca Kimble, pre-eminent Staff Specialist, Obstetrics & Gynaecology, Royal Brisbane and Women's Hospital
Dr Renuka Sekar, clinical lead, Maternal Fetal Medicine Specialist, Royal Brisbane and Women's Hospital

QCG Program Officer
Ms Emily Holmes
Ms Jacinta Lee

Working Party Members
Dr Tegan Allin, Rural Generalist, Torres and Cape Hospital and Health Service
Mrs Josephine Bell, Registered Midwife, Maternity Unit, Stanthorpe Hospital
Dr Elize Bolton, Clinical Director, Obstetrics and Gynaecology, Bundaberg Hospital
Mrs Kym Boyes, Nurse Practitioner, Community Health, Torres Cape HHS
Ms Bronwyn Brabrook, Advanced Social Work, Women's, Children's, and Emergency, Toowoomba Hospital
Mrs Susan Callan, Clinical Nurse Midwife Consultant, Bereavement, Royal Brisbane and Women's Hospital
Mrs Katie Cameron, Consumer Representative, Maternity Consumer Network
Ms Eileen Cooke, Parent Support, Preterm Infants Parent Association (PIPA)
Professor Caroline De Costa, James Cook University, College of Medicine
Ms Andrea Densley, Nurse Unit Manager, Child Health, Department of Health
Mrs Carole Dodd, Registered Midwife/Clinical Nurse, Pregnancy Loss, Caboolture Hospital
Associate Professor Greg Duncombe, Pre-eminent Staff Specialist, Maternal Fetal Medicine, Royal Brisbane and Women's Hospital
Ms Joanne Ellerington, Manager, Data Collections, Statistical Services Branch, Queensland Health
Dr Janet Fairweather, Medical Doctor, Marie Stopes Australia
Dr Leigh Grant, Senior Medical Officer, Obstetrics and Gynaecology, Rockhampton Hospital
Mrs Louise Griffiths, Registered Midwife/Nurse, Maternal Fetal Medicine, Royal Brisbane and Women's Hospital
Dr Carmon Guy, Senior Medical Officer, Cooktown Hospital
Mrs Helen Hicks, Registered Midwife, Maternity Services, Caboolture Hospital
Mrs Debra Hudson, Registered Midwife, Pregnancy Loss Coordinator, Cairns Hospital
Dr Jill Hunady, Regional Medical Officer, True Relationships and Reproductive Health
Mrs Louise Johnston, Clinical Midwifery Consultant (Acting), Women's and Newborn Services, Royal Brisbane and Women's Hospital
Dr Shveta Kapoor, Obstetrician Gynaecologist, Ipswich Hospital
Mrs Linda Keidge, Senior Social Worker, Maternity and Paediatrics, Bundaberg Hospital
Ms Daile Kelleher, Manager, Children by Choice
Mrs Melanie McKenzie, Consumer Representative, Harrison's Little Wings
Dr Catriona Melville, Deputy Medical Director, Marie Stopes Australia
Dr Rebecca Mitchell, Senior Obstetrics and Gynaecology Registrar, Cairns Hospital
Mrs Ange Pearson, Senior Social Worker, Princess Alexandra Hospital
Dr Scott Petersen, Staff Specialist, Maternal Fetal Medicine, Mater Mothers' Hospital
Mrs Elizabeth Power, Clinical Nurse, Cairns Sexual Health Service, Cairns Hospital
Ms Jacqueline Plazina, Clinical Nurse, NICU/NeoRSQ, Royal Brisbane and Women's Hospital
Mrs Catherine Rawlinson, Service Development Leader, Centre for Perinatal and Infant Mental Health
Dr Jane Reeves, Staff Specialist, Obstetrics and Gynaecology, Sunshine Coast University Hospital
Dr Alan Richardson, Director of Medical Services, Roma Hospital
Dr Susan Roberts, Psychiatrist, Perinatal Mental Health, Gold Coast University Hospital
Mrs Christine Roomburg, Registered Nurse/Midwife, Marie Stopes Australia
Dr Shannyn Rosser, Maternal Fetal Medicine Fellow (non-accredited), Royal Brisbane and Women's Hospital
Mrs Mary-Ellen Russellhuber, Registered Midwife, Maternity Unit, Caboolture Hospital
Mrs Sharon Stockell, Business Manager, True Relationships and Reproductive Health
Ms Rhonda Taylor, Clinical Midwifery Consultant, Birth Suite, The Townsville Hospital
Ms Siân Tooker, Senior Counsellor, Children by Choice

Queensland Clinical Guidelines Team
Associate Professor Rebecca Kimble, Director
Ms Jacinta Lee, Manager
Ms Stephanie Sutherns, Clinical Nurse Consultant
Ms Cara Cox, Clinical Nurse Consultant
Ms Emily Holmes, Clinical Nurse Consultant
Dr Brent Knack, Program Officer

Funding
This clinical guideline was funded by Queensland Health, Healthcare Improvement Unit.